



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Ondansetron hydrochloride

Cat. No.:	HY-B0002
CAS No.:	99614-01-4
Molecular Formula:	C ₁₈ H ₂₀ ClN ₃ O
Molecular Weight:	329.82
Target:	5-HT Receptor
Pathway:	GPCR/G Protein; Neuronal Signaling
Storage:	4°C, sealed storage, away from moisture and light * The compound is unstable in solutions, freshly prepared is recommended.



H-Cl

BIOLOGICAL ACTIVITY

Description	<p>Ondansetron hydrochloride (GR 38032 hydrochloride; SN 307 hydrochloride) is a serotonin 5-HT₃ receptor antagonist used mainly as an antiemetic (to treat nausea and vomiting), often following chemotherapy. Target: 5-HT Receptor IC₅₀ Value: in vitro: 5-HT evoked transient inward currents (EC₅₀ = 3.4 μM; Hill coefficient = 1.8) that were blocked by the 5-HT₃ receptor antagonist ondansetron (IC₅₀ = 103 pM) [1]. The 5-HT_{3A} receptor antagonist ondansetron (0.3 nM) reversibly inhibited the 5-HT (30 μM) signal by 70% and at 3 nM it abolished the response [2]. in vivo: Acute ondansetron administration at the lowest dose (0.1 mg/kg, IP) tested had no effect, while other doses (0.33 and 1 mg/kg, IP) produced improvements in auditory gating [3]. Different doses of ondansetron were injected intraperitoneally (i.p.) at fixed times during the day to determine both the sublethal (TD₅₀) and lethal (LD₅₀) doses, which were, respectively, 3.7 ± 0.6 mg/kg and 4.6 ± 0.5 mg/kg [4]. ondansetron (0.25-1.0 mg/kg, subcutaneously) given before the challenge dose of ethanol (2.4 g/kg, intraperitoneally) injection, significantly and dose dependently attenuated the expression of sensitization. In addition, ondansetron (1.0 mg/kg, subcutaneously) given before ethanol injection on days 1, 4, 7, and 10 significantly blocked the development (days 1, 4, 7, and 10), and expression (day 15) of sensitization to the locomotor stimulant effect of ethanol injection [5]. Toxicity: Ondansetron may be safe in lower doses used to prevent nausea and vomiting in radiation treatment or postoperatively. However, as there is a report that a lower dose of ondansetron prolonged the QT interval in healthy volunteers, this needs to be clarified by the FDA [6].</p>
IC₅₀ & Target	5-HT ₃ Receptor

CUSTOMER VALIDATION

- Int J Pharm. 2015 Dec 30;496(1):33-41.
- Prog Neuropsychopharmacol Biol Psychiatry. 2022 Nov 30;110689.
- J Ethnopharmacol. 2024 Jan 5:117703.
- Eur J Pharm Sci. 2023 May 22;106475.
- Journal of Radiation Research and Applied Sciences. 2023 Dec, 16(4), 100682.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Brown AM, et al. Ion permeation and conduction in a human recombinant 5-HT₃ receptor subunit (h5-HT_{3A}). *J Physiol*. 1998 Mar 15;507 (Pt 3):653-65.
- [2]. Barann M, et al. Recombinant human 5-HT_{3A} receptors in outside-out patches of HEK 293 cells: basic properties and barbiturate effects. *Naunyn Schmiedebergs Arch Pharmacol*. 2000 Sep;362(3):255-65.
- [3]. Wildeboer KM, et al. Ondansetron results in improved auditory gating in DBA/2 mice through a cholinergic mechanism. *Brain Res*. 2009 Dec 1;1300:41-50.
- [4]. Khedhaier A, et al. Circadian rhythms in toxic effects of the serotonin antagonist ondansetron in mice. *Chronobiol Int*. 2003 Nov;20(6):1103-16.
- [5]. Umathe SN, et al. The 5-HT₃ receptor antagonist, ondansetron, blocks the development and expression of ethanol-induced locomotor sensitization in mice. *Behav Pharmacol*. 2009 Feb;20(1):78-83.
- [6]. Doggrell SA, et al. Cardiac safety concerns for ondansetron, an antiemetic commonly used for nausea linked to cancer treatment and following anaesthesia. *Expert Opin Drug Saf*. 2013 May;12(3):421-31.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA